Contributions
Abstract: PB1454
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Immunomodulatory medications including monoclonal antibodies are widely used in the treatment of many hematological malignancies, however their use during the COVID-10 pandemic was associated with worse outcome for some patients.
Aims
To evaluate the immune & hematologic characteristics of patient demographics, time from last chemo-immunotherapy, cancer status at time of infection, severity of COVID-19 infection, COVID-19 CT value, time of clearance, Immunoglobulin levels & IL-6 levels
Methods
To evaluate the immune & hematologic characteristics of patient demographics, time from last chemo-immunotherapy, cancer status at time of infection, severity of COVID-19 infection, COVID-19 CT value, time of clearance, Immunoglobulin levels & IL-6 levels
Results
during the study period we reviewed 50 patients with hematological malignancy who were diagnosed with confirmed COVID-19 since March 2020, 8 patients fit the inclusion criteria, all of them were having advanced stage lymphoma at some point.
4 patients died, 75% of them had ECOG ≥2 & all of them never cleared the COVID-19 virus, 3 patients recovered, 1 is still recovering but still has reactive COVID PCR test, remains in very stable condition.
the other 4 patents who recovered, 2 cleared their infection within 14 days, 1 patient had reinfection within 3 months & 1 still has positive COVID PCR after 30 days of infection, all of them were in complete remission at time of COVID-19 infection & all of them has mild infection
Conclusion
Treatment with monoclonal antibodies including regimens during COVID-19 pandemic should be used with caution in regards of its outstanding benefits vs risk of severe & fatal COVID-19 infection in this critical point of time. It was noticed that achieving hematologocal remission is an important factor in patient survival & recovery from COVID-19 infection, patient who died had lower COVID-19 PCR CT values than the patients who survived & never cleared the virus, however survivors mostly had delayed viral clearance than general population in general
Keyword(s): COVID-19, Immune therapy, Monoclonal antibody, NHL
Abstract: PB1454
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Immunomodulatory medications including monoclonal antibodies are widely used in the treatment of many hematological malignancies, however their use during the COVID-10 pandemic was associated with worse outcome for some patients.
Aims
To evaluate the immune & hematologic characteristics of patient demographics, time from last chemo-immunotherapy, cancer status at time of infection, severity of COVID-19 infection, COVID-19 CT value, time of clearance, Immunoglobulin levels & IL-6 levels
Methods
To evaluate the immune & hematologic characteristics of patient demographics, time from last chemo-immunotherapy, cancer status at time of infection, severity of COVID-19 infection, COVID-19 CT value, time of clearance, Immunoglobulin levels & IL-6 levels
Results
during the study period we reviewed 50 patients with hematological malignancy who were diagnosed with confirmed COVID-19 since March 2020, 8 patients fit the inclusion criteria, all of them were having advanced stage lymphoma at some point.
4 patients died, 75% of them had ECOG ≥2 & all of them never cleared the COVID-19 virus, 3 patients recovered, 1 is still recovering but still has reactive COVID PCR test, remains in very stable condition.
the other 4 patents who recovered, 2 cleared their infection within 14 days, 1 patient had reinfection within 3 months & 1 still has positive COVID PCR after 30 days of infection, all of them were in complete remission at time of COVID-19 infection & all of them has mild infection
Conclusion
Treatment with monoclonal antibodies including regimens during COVID-19 pandemic should be used with caution in regards of its outstanding benefits vs risk of severe & fatal COVID-19 infection in this critical point of time. It was noticed that achieving hematologocal remission is an important factor in patient survival & recovery from COVID-19 infection, patient who died had lower COVID-19 PCR CT values than the patients who survived & never cleared the virus, however survivors mostly had delayed viral clearance than general population in general
Keyword(s): COVID-19, Immune therapy, Monoclonal antibody, NHL